Comparison · NCT02981407-54a4c156
Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Composite of All-cause Mortality, Nonfatal Myocardial Reinfarction, Ischemia Driven Unscheduled Coronary Revascularization, or Readmission to the Hospital for Ischemic Cardiac Diagnosis
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Composite of All-cause Mortality, Nonfatal Myocardial Reinfarction, Ischemia Driven Unscheduled Coronary Revascularization, or Readmission to the Hospital for Ischemic Cardiac Diagnosis. Trial comparisons, record NCT02981407-54a4c156. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02981407-54a4c156
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.174 | 0.157 | 0.192 | wilson | |
| Risk in group 2 | 0.196 | 0.178 | 0.215 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0218 | -0.0474 | 0.00395 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.889 | 0.773 | 1.02 | log | |
| Odds ratio, group 1 over group 2 | 0.865 | 0.729 | 1.03 | log | |
| Number needed to treat, for one fewer participant with the outcome on Liberal Transfusion Strategy than on Restrictive Transfusion Strategy | 46 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Liberal Transfusion Strategy | Red blood cell transfusion - One unit of packed red cells is transfused following randomization followed by enough red blood cell units to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days.~Red Blood Cell Transfusion: Transfusion of packed red blood cell units | 305 | 1,755 | OG000 |
| Group 2 | Restrictive Transfusion Strategy | Permitted to receive a red blood cell transfusion if the blood count is below 8 g/dL and the physician believes it is in the patient's best interest. A transfusion will be strongly recommended if the blood count drops to less than 7 g/dL. If the patient has symptoms of angina (e.g., chest discomfort described as pressure or heaviness) that do not go away with medication, a blood transfusion will be ordered regardless of the blood count.~Red Blood Cell Transfusion: Transfusion of packed red blood cell units | 342 | 1,749 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Composite of All-cause Mortality, Nonfatal Myocardial Reinfarction, Ischemia Driven Unscheduled Coronary Revascularization, or Readmission to the Hospital for Ischemic Cardiac Diagnosis
- Description
- Time frame
- Within 30 days of randomization
- Population
Source ClinicalTrials.gov
Trial
- Title
- Myocardial Ischemia and Transfusion
- NCT number
- NCT02981407
- Phases
- PHASE3
- Conditions
- Myocardial Infarction, Anemia
- Interventions
- Red Blood Cell Transfusion
- Lead sponsor
- Rutgers, The State University of New Jersey
- Results first posted
- 2024-05-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02981407?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02981407-54a4c156